{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T05:45:11Z","timestamp":1748497511157,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EMD Serono, Inc","award":["10.13039\/100004755"],"award-info":[{"award-number":["10.13039\/100004755"]}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Combination immunotherapy is now considered the standard first-line therapy for patients with metastatic clear cell renal cell carcinoma (mccRCC) after multiple clinical trials demonstrated improved overall survival compared with single-agent tyrosine kinase inhibitors. Cabozantinib modulates critical components of the immune system, such as decreasing regulatory T cells and increasing T-effector cell populations, and is approved for the treatment of mRCC. Avelumab is a human IgG1 monoclonal antibody that binds to programmed death-ligand 1 protein and inhibits the interaction with PD-1. This phase I trial assessed the safety and clinical activity of avelumab and cabozantinib combination therapy in mccRCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study was a phase I, 3+3 dose escalation clinical trial. The primary endpoint was the safety and identification of the recommended phase II dose (RP2D). Secondary endpoints included objective response rate (ORR) and radiographic progression-free survival (rPFS). There were 3 dose cohorts: cabozantinib 20, 40, and 60 mg\/day, each combined with avelumab (10 mg\/kg intravenously every 2 weeks). An additional 3 patients were included in the final dose cohort as a confirmation of the RP2D. No dose modifications were allowed for avelumab, but dose delays were permitted. Both dose reductions and holds were allowed for cabozantinib. Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was used to determine ORR, and treatment beyond progression was allowed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twelve patients with newly diagnosed mccRCC were enrolled from July 2018 until March 2020. Three patients were enrolled in the 20 and 40 mg cohorts each, and 6 were enrolled in the 60 mg cohort. The International Metastatic RCC Database Consortium (IMDC) risk categories for these patients were: 4 patients (favorable risk), 6 patients (intermediate risk), and 2 patients (poor risk). No dose-limiting toxicities (DLTs) were observed in any cohort. Six patients developed serious adverse events related to study treatment after the DLT window period. Immune-related adverse events (iRAEs) were reported in 11 patients; fatigue and diarrhea were the most common (each with n = 4, 33.3%), followed by maculopapular rash and hand-foot syndrome (each with n = 3, 25%). Dose reductions were required in 5 of 6 patients in the cabozantinib 60 mg cohort after the DLT period. One patient discontinued avelumab due to irAE (nephritis), while none discontinued cabozantinib due to toxicity. The ORR was 50%, with one complete response (CR) and 5 partial responses (PR). The disease control rate (CR + PR + stable disease) was noted in 92% of the patients. Radiological PFS survival rate at 6 and 12 months was reported in 67.7% and 33.5% of patients, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Combination therapy with avelumab and cabozantinib is safe and showed preliminary clinical activity in mccRCC. Even though the DLT was not met in any of the 3 cohorts, the recommended RP2D dose for the combination is cabozantinib 40 mg\/day due to a high incidence of grade 2 toxicity for cabozantinib 60 mg\/day after the DLT period. (ClinicalTrials.gov Identifier: NCT03200587)<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad019","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T18:29:13Z","timestamp":1679596153000},"page":"737-e693","source":"Crossref","is-referenced-by-count":4,"title":["Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma"],"prefix":"10.1093","volume":"28","author":[{"given":"Haoran","family":"Li","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-6882","authenticated-orcid":false,"given":"Kamal Kant","family":"Sahu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Brundage","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallory","family":"Benson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M","family":"Boucher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumati","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josiah","family":"Hawks","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepika","family":"Sirohi","sequence":"additional","affiliation":[{"name":"Department of Pathology, ARUP Institute for Clinical and Experimental Pathology, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin L","family":"Maughan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"issue":"2","key":"2023080322082191400_CIT0001","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/oncolo\/oyab056","article-title":"First-line treatments for metastatic clear cell renal cell carcinoma: an ever-enlarging landscape","volume":"27","author":"Gulati","year":"2022","journal-title":"Oncologist"},{"issue":"19","key":"2023080322082191400_CIT0002","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"2023080322082191400_CIT0003","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur J Cancer."},{"issue":"14","key":"2023080322082191400_CIT0004","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med."},{"issue":"12","key":"2023080322082191400_CIT0005","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med."},{"issue":"9","key":"2023080322082191400_CIT0006","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med."},{"key":"2023080322082191400_CIT0007","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-319-91442-8_5","article-title":"Multi-kinase inhibitor of MET, AXL, RET, and VEGFR2","volume":"211","author":"Gr\u00fcllich","year":"2018","journal-title":"Recent Results Cancer Res."},{"issue":"12","key":"2023080322082191400_CIT0008","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1158\/1535-7163.MCT-18-1399","article-title":"Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence","volume":"18","author":"Bergerot","year":"2019","journal-title":"Mol Cancer Ther."},{"issue":"10","key":"2023080322082191400_CIT0009","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"16_suppl","key":"2023080322082191400_CIT0010","doi-asserted-by":"crossref","first-page":"TPS4607","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4607","article-title":"MAIN-CAV: phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"2023080322082191400_CIT0011","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/annonc\/mdu184","article-title":"A phase I study of cabozantinib (XL184) in patients with renal cell cancer","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol."},{"issue":"1","key":"2023080322082191400_CIT0012","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s40425-019-0746-2","article-title":"Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial","volume":"7","author":"Vaishampayan","year":"2019","journal-title":"J ImmunoTher Cancer."},{"issue":"4","key":"2023080322082191400_CIT0013","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/1756287215576443","article-title":"Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma","volume":"7","author":"Psutka","year":"2015","journal-title":"Ther Adv Urol"},{"issue":"19","key":"2023080322082191400_CIT0014","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med."},{"issue":"18","key":"2023080322082191400_CIT0015","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.3390\/cancers13184606","article-title":"Thrombotic complications associated with immune checkpoint inhibitors","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"key":"2023080322082191400_CIT0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2021.06.018","article-title":"Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: a retrospective multicentric cohort study","volume":"205","author":"Desch\u00eanes-Simard","year":"2021","journal-title":"Thromb Res."},{"issue":"31","key":"2023080322082191400_CIT0017","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J Clin Oncol."},{"issue":"33","key":"2023080322082191400_CIT0018","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.21.00939","article-title":"Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study","volume":"39","author":"Pal","year":"2021","journal-title":"J Clin Oncol."},{"issue":"6_suppl","key":"2023080322082191400_CIT0019","doi-asserted-by":"crossref","first-page":"TPS370","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS370","article-title":"CONTACT-03: randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on\/after immune checkpoint inhibitor (ICI) treatment in patients with advanced\/metastatic renal cell carcinoma","volume":"39","author":"Pal","year":"2021","journal-title":"J Clin Oncol."},{"article-title":"Phase III study of cabozantinib in combination with nivolumab and ipilimumab in previously untreated advanced renal cell carcinoma of IMDC intermediate or poor risk (COSMIC-313)","author":"Choueiri","key":"2023080322082191400_CIT0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.070"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/737\/51034846\/oyad019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/737\/51034846\/oyad019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:09:47Z","timestamp":1691100587000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/8\/737\/7084885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,3,23]]},"published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad019","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,3,23]]}}}